Scienture Holdings Inc (NASDAQ:SCNX) stock fell sharply, dropping 43.7%, after the company announced a registered direct offering of common stock at a steep discount to its current market price.
The pharmaceutical holding company entered into a securities purchase agreement with institutional investors to sell 3,225,000 shares at $1.20 per share. The offering, expected to close on August 15, 2025, is projected to raise roughly $3.9 million in gross proceeds before fees and expenses.
The discounted offering price, significantly below recent trading levels, triggered the dramatic decline in Scienture’s share price. Maxim Group LLC is serving as the sole placement agent for the transaction.
Scienture Holdings functions as a holding company for its existing and planned pharmaceutical operations, focusing on developing, marketing, and distributing specialty products designed to address unmet market needs. The offering remains subject to customary closing conditions.
Scienture Holdings stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.